PEN

Penumbra Inc. (PEN) | Rumor.io

Penumbra

PEN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,791

Bullish sentiment (50-day avg)21%

Price to earnings ratio78.1

Market capitalization12.6B

Earnings per share4.08

Dividend yield (TTM)—

Revenue (annual)1.4B

Net income (annual)177.7M

Social

What share of all stock conversation is about PEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jan 16

Boston Scientific has agreed to acquire Penumbra, Inc. ($PEN) for $14.5 billion in a cash-and-stock deal, expanding its medical device portfolio.
Penumbra's stock price has risen by 11.82% following the acquisition announcement, with a market capitalization of $13.73 billion and a P/E ratio of 83.25.
The acquisition is expected to be a significant consolidation in the medical device sector, with Boston Scientific targeting a price of $374 for Penumbra's stock.

Generated by AI

Sentiment

Of the messages about PEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% new	81.78% +8.25
Bearish	0%	0%	0% -100	18.22% -8.25

Dec 16

Analysts covering Penumbra have a conflict of interest due to their employers' underwriting fees, which can reach millions.
Penumbra's financial performance is concerning, with a free cash flow yield of -10% and a high price-to-revenue ratio of 12 times.
The company's management has been accused of insider trading and negligence, with analysts and short sellers questioning their actions.

Generated by AI

Topics

Of the messages about PEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	61.16%
Technical Analysis	—	—	—	13.87%
Analysts	—	—	—	13.53%
Controversies	—	—	—	0.14%
Earnings	—	—	—	0.74%
Macro	—	—	—	10.55%

Jan 15

Boston Scientific is acquiring Penumbra for $14.5 billion in a cash and stock deal, valuing each Penumbra share at $374.
The acquisition will be completed in 2026, with Penumbra stockholders having the option to receive cash or Boston Scientific shares.
The deal is expected to be paid 73% in cash and 27% in Boston Scientific shares, with Penumbra's revenue guidance for FY25 remaining at $1.4 billion.

Generated by AI

Community

Of the messages about PEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	60.19%
Newcomers	100%	100%	100%	39.81%

Regulars· Jan 15

Penumbra, Inc. is being acquired by Boston Scientific for $374 per share in a deal valued at $14.5 billion, with closing subject to approvals.
The acquisition will see Penumbra become a wholly owned subsidiary of Boston Scientific, expanding its cardiovascular presence and addressing cardiovascular diseases.
Penumbra reported a 22% Q4 revenue growth ahead of the acquisition, and its preliminary update on 2025 financial results suggests a strong performance despite the pending merger.

Newcomers· Jan 16

Penumbra, Inc. (PEN) has reached a record high after announcing a $14.5B merger agreement with Boston Scientific, marking significant consolidation in the medical device sector.
The acquisition has led to a surge in Penumbra's stock price, with a current price of $351.60 (+12.2% today) and a market cap of $13.73B, with analyst targets ranging from $336.06 to $374.
The deal is expected to expand Boston Scientific's heart device portfolio and provide Penumbra's thrombectomy company with a substantial cash-and-stock deal worth $14.5B.

Generated by AI

News

Reasons to Retain Penumbra Stock in Your Portfolio for Now

PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

13d agoYahoo Finance UK

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

ALAMEDA, Calif. , July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

2mo agoBarchart.com

Penumbra Inc earnings missed by $0.28, revenue topped estimates

2mo agoInvesting.com

Penumbra: Q2 Earnings Snapshot

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

2mo agoYahoo Finance

Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study

Penumbra (NYSE:PEN) received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The THUNDER study reported strong safety and efficacy results for THUNDERBOLT in stroke care. A leading stroke center has begun using THUNDERBOLT in clinical practice, expanding its real world footprint. Penumbra, traded on the NYSE under ticker PEN, focuses on medical devices for neuro and vascular conditions, including stroke. The FDA clearance...

2mo agoYahoo Finance

Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued

Penumbra (PEN) is back in focus after Novant Health reported successful use of its newly cleared THUNDERBOLT computer assisted vacuum thrombectomy system at a North Carolina comprehensive stroke center. See our latest analysis for Penumbra. At a share price of $318.73, Penumbra has seen a 1 year total shareholder return of 36.74%, while the 3 year and 5 year total shareholder returns of 3.46% and 19.72% suggest more moderate longer term progress as investors weigh new products like...

2mo agoYahoo Finance

Also Discussed

Investors talking about PEN also mention

#	Name	Attention
1	BlackRock Enhanced Global Dividend TrustBOE	0%0
2	Lotus Technology Inc. ADRLOT	0%0
3	Invesco FTSE RAFI Developed Markets ex-U.S. Small-Mid ETFPDN	0.01%new
4	AGE - AgeX Therapeutics, Inc.	——
5	WisdomTree Target Range FundGTR	0%new
6	Ameren CorporationAEE	0%new
7	Encompass Health CorporationEHC	0%0
8	Henry Schein, Inc.HSIC	0%0
9	Clough Global Opportunities FundGLO	0.01%-0.1
10	VanEck Steel ETFSLX	0%-0.01

Penumbra Inc.

Healthcare
Medical Devices

Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.

Website

Location

One Penumbra Place

Alameda, CA, 94502

United States

Social

What share of all stock conversation is about PEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Jan 16

Boston Scientific has agreed to acquire Penumbra, Inc. ($PEN) for $14.5 billion in a cash-and-stock deal, expanding its medical device portfolio.
Penumbra's stock price has risen by 11.82% following the acquisition announcement, with a market capitalization of $13.73 billion and a P/E ratio of 83.25.
The acquisition is expected to be a significant consolidation in the medical device sector, with Boston Scientific targeting a price of $374 for Penumbra's stock.

Generated by AI

Sentiment

Of the messages about PEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% new	81.78% +8.25
Bearish	0%	0%	0% -100	18.22% -8.25

Dec 16

Analysts covering Penumbra have a conflict of interest due to their employers' underwriting fees, which can reach millions.
Penumbra's financial performance is concerning, with a free cash flow yield of -10% and a high price-to-revenue ratio of 12 times.
The company's management has been accused of insider trading and negligence, with analysts and short sellers questioning their actions.

Generated by AI

Topics

Of the messages about PEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	61.16%
Technical Analysis	—	—	—	13.87%
Analysts	—	—	—	13.53%
Controversies	—	—	—	0.14%
Earnings	—	—	—	0.74%
Macro	—	—	—	10.55%

Jan 15

Boston Scientific is acquiring Penumbra for $14.5 billion in a cash and stock deal, valuing each Penumbra share at $374.
The acquisition will be completed in 2026, with Penumbra stockholders having the option to receive cash or Boston Scientific shares.
The deal is expected to be paid 73% in cash and 27% in Boston Scientific shares, with Penumbra's revenue guidance for FY25 remaining at $1.4 billion.

Generated by AI

Community

Of the messages about PEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	60.19%
Newcomers	100%	100%	100%	39.81%

Regulars· Jan 15

Penumbra, Inc. is being acquired by Boston Scientific for $374 per share in a deal valued at $14.5 billion, with closing subject to approvals.
The acquisition will see Penumbra become a wholly owned subsidiary of Boston Scientific, expanding its cardiovascular presence and addressing cardiovascular diseases.
Penumbra reported a 22% Q4 revenue growth ahead of the acquisition, and its preliminary update on 2025 financial results suggests a strong performance despite the pending merger.

Newcomers· Jan 16

Penumbra, Inc. (PEN) has reached a record high after announcing a $14.5B merger agreement with Boston Scientific, marking significant consolidation in the medical device sector.
The acquisition has led to a surge in Penumbra's stock price, with a current price of $351.60 (+12.2% today) and a market cap of $13.73B, with analyst targets ranging from $336.06 to $374.
The deal is expected to expand Boston Scientific's heart device portfolio and provide Penumbra's thrombectomy company with a substantial cash-and-stock deal worth $14.5B.

Generated by AI

Penumbra

Social

Jan 16

Dec 16

Jan 15

Regulars· Jan 15

Newcomers· Jan 16

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Penumbra Inc earnings missed by $0.28, revenue topped estimates

Penumbra: Q2 Earnings Snapshot

Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study

Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued

Also Discussed

Penumbra Inc.

Company Information

Location

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Penumbra Inc earnings missed by $0.28, revenue topped estimates

Penumbra: Q2 Earnings Snapshot

Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study

Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued

Also Discussed

Social

Jan 16

Dec 16

Jan 15

Regulars· Jan 15

Newcomers· Jan 16